Workflow
QTORIN™ 3.9% rapamycin anhydrous gel
icon
Search documents
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Globenewswire· 2025-08-05 11:30
WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth ...